Esomeprazole
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Postoperative Bariatric Surgery
Conditions
Postoperative Bariatric Surgery
Trial Timeline
Nov 1, 2005 → Aug 1, 2006
NCT ID
NCT00608712About Esomeprazole
Esomeprazole is a approved stage product being developed by AstraZeneca for Postoperative Bariatric Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT00608712. Target conditions include Postoperative Bariatric Surgery.
What happened to similar drugs?
20 of 20 similar drugs in Postoperative Bariatric Surgery were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01370538 | Phase 3 | Completed |
| NCT01370525 | Phase 3 | Completed |
| NCT00474019 | Phase 1 | Completed |
| NCT00427635 | Phase 3 | Completed |
| NCT00384592 | Approved | Completed |
| NCT00318968 | Approved | Completed |
| NCT00608712 | Approved | Completed |
| NCT00251979 | Phase 3 | Completed |
| NCT00392002 | Approved | Completed |
| NCT00242736 | Approved | Completed |
| NCT00291746 | Approved | Completed |
| NCT00206440 | Phase 3 | Terminated |
| NCT00243724 | Phase 3 | Completed |
| NCT00524251 | Pre-clinical | Completed |
| NCT00251966 | Phase 3 | Completed |
| NCT00251901 | Phase 3 | Completed |
| NCT00120315 | Approved | Completed |
| NCT00574925 | Approved | Completed |
| NCT00222131 | Phase 2 | Completed |
| NCT00318084 | Approved | Completed |
Competing Products
20 competing products in Postoperative Bariatric Surgery